
NeuroPsyCAD leverages artificial intelligence to enhance the diagnosis of neuropsychiatric disorders by analyzing brain scan data, providing clinicians with timely and accurate reports that include probability scores for various diseases. This innovative approach allows for earlier diagnosis and personalized treatment, significantly reducing costs associated with traditional diagnostic methods. With a focus on improving patient outcomes, NeuroPsyCAD aims to transform the subjective practices in neurology and psychiatry into a more objective and data-driven process, positioning itself as a leader in the neuroimaging biomarker space.

NeuroPsyCAD leverages artificial intelligence to enhance the diagnosis of neuropsychiatric disorders by analyzing brain scan data, providing clinicians with timely and accurate reports that include probability scores for various diseases. This innovative approach allows for earlier diagnosis and personalized treatment, significantly reducing costs associated with traditional diagnostic methods. With a focus on improving patient outcomes, NeuroPsyCAD aims to transform the subjective practices in neurology and psychiatry into a more objective and data-driven process, positioning itself as a leader in the neuroimaging biomarker space.
Headquarters: Braga, Portugal
Founded: May 2017
Product: AI-powered neuroimaging analysis producing patient-personalized diagnostic reports
Last disclosed funding: Grant (Dec 2017) led by EASME
Employee count (public profile): 3
Neuropsychiatric diagnosis; neuroimaging biomarkers
2017
Healthtech
60000.00 USD
Last disclosed funding round